Last reviewed · How we verify
NCT03860792: TDAD
Therapeutic Diets in Alzheimer's Disease
Completed
NA
Last updated 17 December 2025
What this trial tests
NA trial testing Ketogenic Diet in Alzheimer Disease in 84 participants. Completed in 20 June 2025.
Timeline
15 October 2019
Primary endpoint
23 May 2025
23 May 2025
20 June 2025
Quick facts
| Lead sponsor | University of Kansas Medical Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 84 |
| Start date | 15 October 2019 |
| Primary completion | 23 May 2025 |
| Estimated completion | 20 June 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Ketogenic Diet — full drug profile →
- Therapeutic Lifestyles Changes Diet
Conditions studied
- Alzheimer Disease — all drugs for Alzheimer Disease →
Sponsor
University of Kansas Medical Center
Who can join
Adults 50 to 90, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
By doing this study, researchers hope to learn how the ketogenic and Therapeutic Lifestyles Changes diets affect cognition in patients with Alzheimer's disease.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Central and Peripheral Metabolic Defects Contribute to the Pathogenesis of Alzheimer's Disease: Targeting Mitochondria for Diagnosis and Prevention.
Peng Y, Gao P, Shi L, Chen L, et al · · 2020 · cited 84× · PMID 32050773 · DOI 10.1089/ars.2019.7763 -
Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer's Disease.
Toniolo S, Sen A, Husain M. · · 2020 · cited 74× · PMID 33297460 · DOI 10.3390/ijms21239318 -
Mitophagy and the Brain.
Swerdlow NS, Wilkins HM. · · 2020 · cited 51× · PMID 33352896 · DOI 10.3390/ijms21249661 -
To Keto or Not to Keto? A Systematic Review of Randomized Controlled Trials Assessing the Effects of Ketogenic Therapy on Alzheimer Disease.
Grammatikopoulou MG, Goulis DG, Gkiouras K, Theodoridis X, et al · · 2020 · cited 44× · PMID 32597927 · DOI 10.1093/advances/nmaa073 -
Dietary Neuroketotherapeutics for Alzheimer's Disease: An Evidence Update and the Potential Role for Diet Quality.
Taylor MK, Swerdlow RH, Sullivan DK. · · 2019 · cited 42× · PMID 31443216 · DOI 10.3390/nu11081910 -
Vitamin D in Neurological Diseases.
Plantone D, Primiano G, Manco C, Locci S, et al · · 2022 · cited 38× · PMID 36613531 · DOI 10.3390/ijms24010087 -
Efficacy and Safety of Ketone Supplementation or Ketogenic Diets for Alzheimer's Disease: A Mini Review.
Lilamand M, Mouton-Liger F, Di Valentin E, Sànchez Ortiz M, et al · · 2021 · cited 24× · PMID 35111799 · DOI 10.3389/fnut.2021.807970 -
Type 3 diabetes and metabolic reprogramming of brain neurons: causes and therapeutic strategies.
Meng X, Zhang H, Zhao Z, Li S, et al · · 2025 · cited 19× · PMID 39966707 · DOI 10.1186/s10020-025-01101-z
Verify or expand the search:
- PubMed search for NCT03860792
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ketogenic Diet
Trials testing the same drug.
- NCT07121894 — Ketogenic Intervention for Bipolar Depression · NA · recruiting
- NCT06894004 — Mechanism of Ketogenic Diet-Induced Hypercholesterolemia · NA · recruiting
- NCT06515912 — Ketogenic Diet in Healthy Adults With Differing BMI · NA · completed
- NCT06503809 — Efficacy and Safety of a Ketogenic Diet in Type 1 Diabetes · NA · recruiting
- NCT06325644 — Well-Formulated Ketogenic Diet Polycystic Kidney Disease · NA · recruiting
Other recruiting trials for Alzheimer Disease
Currently open trials in the same condition.
- NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
- NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
- NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
- NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
- NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting
Other University of Kansas Medical Center trials
Trials by the same sponsor.
- NCT06636214 — Adapting Changing Talk: Online (CHATO) to CHATO-Inclusive · NA · not yet recruiting
- NCT07528963 — KanSurvive 2.0: Testing Enhanced Models of Cancer Survivorship Care for Rural Cancer Survivors in Primary Care Practice · NA · enrolling by invitation
- NCT07463755 — Low-Fidelity Driving Simulator Training in Parkinson's Disease. · NA · not yet recruiting
- NCT07420621 — Preliminary Effectiveness of Enhanced Text Message + Incentives · NA · recruiting
- NCT07491510 — Improving Prenatal Care to Reduce Early Onset Preeclampsia in Low-Income · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03860792 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Kansas Medical Center
- Last refreshed: 17 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03860792.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing